JP2019512464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512464A5 JP2019512464A5 JP2018543153A JP2018543153A JP2019512464A5 JP 2019512464 A5 JP2019512464 A5 JP 2019512464A5 JP 2018543153 A JP2018543153 A JP 2018543153A JP 2018543153 A JP2018543153 A JP 2018543153A JP 2019512464 A5 JP2019512464 A5 JP 2019512464A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 24
- 239000002254 cytotoxic agent Substances 0.000 claims description 18
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000033581 fucosylation Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 9
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 9
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 9
- 208000026278 immune system disease Diseases 0.000 claims description 9
- 230000002489 hematologic effect Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 7
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 150000008267 fucoses Chemical class 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 3
- 239000012626 DNA minor groove binder Substances 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 102000009490 IgG Receptors Human genes 0.000 claims description 3
- 108010073807 IgG Receptors Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000000564 macroglobulinemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 230000002071 myeloproliferative effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 2
- 102000046935 human TNFRSF17 Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 239000001963 growth medium Substances 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030779A JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296594P | 2016-02-17 | 2016-02-17 | |
| US62/296,594 | 2016-02-17 | ||
| US201662396084P | 2016-09-16 | 2016-09-16 | |
| US62/396,084 | 2016-09-16 | ||
| PCT/US2017/018177 WO2017143069A1 (en) | 2016-02-17 | 2017-02-16 | Bcma antibodies and use of same to treat cancer and immunological disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024261A Division JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Division JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512464A JP2019512464A (ja) | 2019-05-16 |
| JP2019512464A5 true JP2019512464A5 (OSRAM) | 2020-03-26 |
| JP7152309B2 JP7152309B2 (ja) | 2022-10-12 |
Family
ID=59562012
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543153A Active JP7152309B2 (ja) | 2016-02-17 | 2017-02-16 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2020024261A Pending JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Withdrawn JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A Pending JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024261A Pending JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Withdrawn JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A Pending JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20170233484A1 (OSRAM) |
| EP (1) | EP3416687A4 (OSRAM) |
| JP (4) | JP7152309B2 (OSRAM) |
| KR (1) | KR102816905B1 (OSRAM) |
| CN (2) | CN116063503A (OSRAM) |
| AU (2) | AU2017219747B2 (OSRAM) |
| BR (1) | BR112018016697A2 (OSRAM) |
| CA (1) | CA3011900A1 (OSRAM) |
| HK (1) | HK1259075A1 (OSRAM) |
| IL (2) | IL260732B2 (OSRAM) |
| MA (1) | MA44254A (OSRAM) |
| MX (2) | MX2018009700A (OSRAM) |
| SG (2) | SG10202007836WA (OSRAM) |
| WO (1) | WO2017143069A1 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1259075A1 (zh) | 2016-02-17 | 2019-11-22 | Seattle Genetics, Inc. | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
| JP7356354B2 (ja) | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
| EP3777895A4 (en) * | 2018-06-26 | 2021-12-22 | ABL Bio Inc. | ANTI-BCMA ANTIBODIES AND ASSOCIATED USE |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020018825A1 (en) | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with bcma specificity and uses thereof |
| WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| WO2020132096A1 (en) * | 2018-12-19 | 2020-06-25 | Seattle Genetics, Inc. | Controlled fucosylation of antibodies |
| SG11202109163YA (en) * | 2019-02-26 | 2021-09-29 | Sorrento Therapeutics Inc | Antigen binding proteins that bind bcma |
| PH12021552123A1 (en) | 2019-03-21 | 2022-08-22 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CN113939319A (zh) | 2019-04-30 | 2022-01-14 | 克里斯珀医疗股份公司 | 靶向cd19的基因工程化t细胞针对b细胞恶性肿瘤的同种异体细胞疗法 |
| CN113784732B (zh) * | 2019-05-07 | 2024-03-22 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| CR20210685A (es) * | 2019-05-31 | 2022-05-13 | Medimmune Llc | Terapia de combinación |
| US20220251228A1 (en) * | 2019-07-30 | 2022-08-11 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| US12479922B2 (en) * | 2019-10-10 | 2025-11-25 | Cytolynx Therapeutics Hong Kong Limited | Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity |
| WO2021136308A1 (en) * | 2020-01-03 | 2021-07-08 | Biosion Inc. | Antibodies binding bcma and uses thereof |
| CN113248611A (zh) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
| CN115279781B (zh) * | 2020-03-26 | 2025-05-09 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| EP4126952A1 (en) * | 2020-03-26 | 2023-02-08 | Seagen Inc. | Methods of treating multiple myeloma |
| CN115955980A (zh) | 2020-04-10 | 2023-04-11 | 思进公司 | 电荷可变接头 |
| EP4240415A1 (en) | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| TW202304514A (zh) | 2021-04-20 | 2023-02-01 | 美商思進公司 | 抗體依賴性細胞毒性之調節 |
| KR20240015670A (ko) | 2021-05-28 | 2024-02-05 | 씨젠 인크. | 안트라사이클린 항체 접합체 |
| AU2022326107A1 (en) | 2021-08-12 | 2024-03-14 | Shanghai Ttm-Bio Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
| WO2023019398A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies, chimeric antigen receptors, and uses thereof |
| TW202327650A (zh) | 2021-09-23 | 2023-07-16 | 美商思進公司 | 治療多發性骨髓瘤之方法 |
| EP4423141A4 (en) * | 2021-10-27 | 2025-12-17 | Janssen Biotech Inc | METHOD FOR IMPROVED BCMA IMMUNOHISTOCHEMIC DETECTION IN HUMAN AND APE TISSUE |
| WO2023116759A1 (zh) * | 2021-12-22 | 2023-06-29 | 上海君实生物医药科技股份有限公司 | 抗bcma抗体及其用途 |
| MX2024011292A (es) | 2022-03-17 | 2024-09-27 | Seagen Inc | Conjugados de camptotecina. |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN119548619A (zh) * | 2023-08-10 | 2025-03-04 | 亘喜生物科技（上海）有限公司 | 一种双靶点car-t细胞在治疗系统性红斑狼疮及其他b细胞自身免疫病中的用途 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| JP4787439B2 (ja) | 1999-08-17 | 2011-10-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ） |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| MXPA02012434A (es) | 2000-06-16 | 2004-09-06 | Cambridge Antibody Tech | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| EP1525213B1 (en) | 2001-10-24 | 2012-06-27 | National Jewish Health | Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto |
| WO2003072713A2 (en) * | 2002-02-21 | 2003-09-04 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| JP2008505607A (ja) | 2004-01-29 | 2008-02-28 | ジェネンテック・インコーポレーテッド | Ｂｃｍａの細胞外ドメインの変異体とその使用法 |
| SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| ES2585357T3 (es) | 2005-07-07 | 2016-10-05 | Seattle Genetics, Inc. | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
| CA2699837C (en) | 2006-12-01 | 2017-06-13 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| SI2406284T1 (sl) * | 2009-03-10 | 2017-01-31 | Biogen Ma Inc. | Anti-bcma protitelesa |
| EP2488200A4 (en) | 2009-10-14 | 2013-06-12 | Merck Sharp & Dohme | APRIL ANTAGONISTS AND METHOD FOR THEIR USE |
| US20130273055A1 (en) | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| CA2819038C (en) | 2010-12-06 | 2023-10-17 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| WO2012118622A1 (en) | 2011-02-19 | 2012-09-07 | Baylor Research Institute | Diagnostic and therapeutic uses for b cell maturation antigen |
| EP2697256A1 (en) | 2011-04-15 | 2014-02-19 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| US20140105915A1 (en) * | 2011-05-27 | 2014-04-17 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - binding proteins |
| CA2889764C (en) * | 2012-11-01 | 2023-10-10 | Martin Lipp | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| JP6061378B2 (ja) * | 2012-11-05 | 2017-01-18 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理装置 |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| JP2016507523A (ja) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体 |
| WO2014140243A1 (en) | 2013-03-15 | 2014-09-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| IL303667A (en) * | 2014-04-30 | 2023-08-01 | Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| KR20240073140A (ko) | 2014-10-29 | 2024-05-24 | 씨젠 인크. | 비-푸코실화된 항-cd40 항체의 용량 및 투여 |
| RS60615B1 (sr) | 2014-11-20 | 2020-08-31 | Hoffmann La Roche | Zajednički laki lanci i postupci upotrebe |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HUE053995T2 (hu) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | B-sejt-érési antigént célzó antitestek és alkalmazási eljárások |
| MX2017013297A (es) | 2015-04-13 | 2018-06-19 | Pfizer | Anticuerpos terapeuticos y sus usos. |
| WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| CN108350073B (zh) | 2015-08-03 | 2022-03-18 | 英格玛布有限责任公司 | 针对bcma的单克隆抗体 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| PT3337824T (pt) | 2015-08-17 | 2020-09-10 | Janssen Pharmaceutica Nv | Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações |
| AU2016353067B2 (en) | 2015-11-13 | 2023-10-05 | Sanford Research | Anti-BCMA polypeptides and proteins |
| JP2019505476A (ja) | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組合せ処置およびその方法 |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| HK1259075A1 (zh) | 2016-02-17 | 2019-11-22 | Seattle Genetics, Inc. | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
| TWI761831B (zh) | 2016-04-01 | 2022-04-21 | 美商凱特製藥公司 | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 |
| AU2018222741A1 (en) * | 2017-02-17 | 2019-09-26 | Unum Therapeutics Inc. | Co-use of anti-BCMA antibody and antibody-coupled T celll receptor (ACTR) in cancer therapy and B cell disorders |
| EP4126952A1 (en) * | 2020-03-26 | 2023-02-08 | Seagen Inc. | Methods of treating multiple myeloma |
-
2017
- 2017-02-16 HK HK19101575.0A patent/HK1259075A1/zh unknown
- 2017-02-16 US US15/434,921 patent/US20170233484A1/en not_active Abandoned
- 2017-02-16 MA MA044254A patent/MA44254A/fr unknown
- 2017-02-16 SG SG10202007836WA patent/SG10202007836WA/en unknown
- 2017-02-16 CA CA3011900A patent/CA3011900A1/en active Pending
- 2017-02-16 KR KR1020187021211A patent/KR102816905B1/ko active Active
- 2017-02-16 JP JP2018543153A patent/JP7152309B2/ja active Active
- 2017-02-16 SG SG11201806261XA patent/SG11201806261XA/en unknown
- 2017-02-16 US US15/999,346 patent/US20190194338A1/en not_active Abandoned
- 2017-02-16 CN CN202211055564.6A patent/CN116063503A/zh active Pending
- 2017-02-16 EP EP17753839.4A patent/EP3416687A4/en active Pending
- 2017-02-16 CN CN201780011604.8A patent/CN108778329B/zh active Active
- 2017-02-16 MX MX2018009700A patent/MX2018009700A/es unknown
- 2017-02-16 AU AU2017219747A patent/AU2017219747B2/en active Active
- 2017-02-16 WO PCT/US2017/018177 patent/WO2017143069A1/en not_active Ceased
- 2017-02-16 BR BR112018016697A patent/BR112018016697A2/pt unknown
- 2017-02-16 IL IL260732A patent/IL260732B2/en unknown
- 2017-02-16 IL IL311107A patent/IL311107A/en unknown
-
2018
- 2018-08-09 MX MX2023000889A patent/MX2023000889A/es unknown
- 2018-10-03 US US16/151,012 patent/US20190023801A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,867 patent/US11078291B2/en active Active
-
2020
- 2020-02-17 JP JP2020024261A patent/JP2020073605A/ja active Pending
-
2021
- 2021-06-25 US US17/358,642 patent/US11767365B2/en active Active
-
2022
- 2022-03-01 JP JP2022030779A patent/JP2022069488A/ja not_active Withdrawn
-
2023
- 2023-08-15 US US18/449,876 patent/US20240109975A1/en not_active Abandoned
- 2023-12-14 AU AU2023282281A patent/AU2023282281A1/en active Pending
- 2023-12-22 JP JP2023216464A patent/JP2024019677A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512464A5 (OSRAM) | ||
| US12453770B2 (en) | CLEC9A binding agents | |
| KR102236259B1 (ko) | 항-lag-3 항체 및 그것의 사용 | |
| JP2019525724A5 (OSRAM) | ||
| AU2014342182B2 (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta TCR -binding polypeptide | |
| JP2008516970A5 (OSRAM) | ||
| RU2013130609A (ru) | Гуманизированные антитела к liv-1 и их применение для лечения рака | |
| EP2703011A3 (en) | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| JP2020515247A5 (OSRAM) | ||
| JP2014506120A5 (OSRAM) | ||
| JP2016513467A5 (OSRAM) | ||
| KR20080047540A (ko) | Ｃｄ20 특이적 결합 분자의 단회 투여 용도 | |
| JP2014039548A5 (OSRAM) | ||
| JP2012530496A5 (OSRAM) | ||
| JP2019525728A5 (OSRAM) | ||
| CN121064331A (zh) | 抗btla抗体 | |
| JP2020523038A5 (OSRAM) | ||
| JP2013509158A5 (OSRAM) | ||
| RU2014108815A (ru) | Новые антитела к фосфорилхолину | |
| EP3599250A1 (en) | Antibody conjugate, and related pharmaceutical composition and application | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JP2013508391A5 (OSRAM) | ||
| JPWO2021186056A5 (OSRAM) | ||
| NZ744381B2 (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| NZ744381A (en) | Bcma antibodies and use of same to treat cancer and immunological disorders |